Project
A Phase II, randomized, double-blind, placebo
Completed ยท 2009 until 2010
Heinzerling Lucie
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2009
End Date
2010
Financing
Industry
Brief description/objective
A Phase II, randomized, double-blind, placebo
-controlled, multi-centre study of the savety and efficacy
of CT 327, Pegylated K-252, formulated as a cream,
when administered twice daily for 14 days to subjects
with Mild-to-Moderate atopic Dermatitis